8-K: Evolus Appoints Tatjana Mitchell as New CFO

Evolus, Inc. announced the appointment of Tatjana Mitchell, a seasoned finance executive from Experian and Zulily, as its new Chief Financial Officer, effective September 8, 2025.

Summary

• Evolus, Inc. appointed Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025.
• Ms. Mitchell brings over 20 years of strategic and operational finance leadership from companies like Experian, Zulily, Forever 21, Macys, Gap Inc., and Marriott International.
• Her compensation package includes an annual base salary of $490,000, a one-time signing bonus of $100,000, and an annual incentive bonus target of 55% of her base salary.
• She will also receive inducement equity grants comprising a stock option valued at $750,000 and Restricted Stock Units (RSUs) valued at $750,000.
• The stock option vests in equal annual installments over four years, while the RSUs vest 50% on the third anniversary and 50% on the fourth anniversary of the grant date.
• The employment agreement includes severance provisions for termination without cause or resignation for good reason, with enhanced benefits in the event of a change in control.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced CFO with a strong track record in relevant industries is a positive development for the company's strategic and financial objectives. The detailed compensation package and clear roles indicate a well-planned executive transition. The forward-looking statements, while containing standard risks, are framed with an optimistic outlook on growth and profitability.

Positives

• Appointment of a highly experienced finance executive, Tatjana Mitchell, with over two decades of leadership in retail, consumer, data, and technology-driven businesses.
• Ms. Mitchell has a proven track record of driving double-digit organic revenue growth, executing acquisitions, expanding customer bases, and delivering consistent EBITDA margin progression at previous roles like Experian.
• Her expertise in scaling brands and driving operational excellence is expected to be instrumental as Evolus expands its portfolio and global footprint.
• The new CFO expressed excitement about joining Evolus at a stage of growth and a shift towards meaningful profitability, aligning with her experience in building innovative, high-performing consumer businesses.

Risks

• Uncertainties associated with the company's ability to comply with the terms and conditions in the Medytox Settlement Agreements.
• Risks related to the company's ability to fund future operations or obtain necessary financing.
• Potential impact of unfavorable global economic conditions on consumer discretionary spending.
• Uncertainties regarding customer and consumer adoption of Jeuveau and Evolysse products.
• Risks concerning the efficiency and operability of the company's digital platform.
• Challenges related to competition and market dynamics in the aesthetic injectable market.
• Uncertainties in successfully launching and commercializing products in new markets, including the Evolysse dermal filler product line in the U.S.
• Risks associated with maintaining regulatory approvals for Jeuveau or obtaining regulatory approvals for new product candidates or indications.
• Reliance on Symatese to achieve regulatory approval for the Evolysse dermal filler product line in the U.S.

Future Outlook

The company's forward-looking statements include anticipated product launches, consumer and customer acceptance of products, and the timing of regulatory submissions and approvals. The new CFO expressed excitement about the company's growth trajectory and shift to meaningful profitability, aiming to deliver on strategic and financial objectives as Evolus strengthens its leadership in performance beauty.

Management Comments

• "Tatjana's exceptional leadership and operational experience in high-growth consumer businesses, combined with her deep expertise in finance and strategy, make her an ideal addition to our executive team." David Moatazedi, President and Chief Executive Officer of Evolus.
• "As Evolus continues to expand its portfolio and global footprint, her experience in scaling brands and driving operational excellence will be instrumental to our continued success." David Moatazedi.
• "I'm excited to join Evolus at such an important stage in its growth trajectory and shift to meaningful profitability." Tatjana Mitchell, Chief Financial Officer.
• "The company's highly differentiated approach to the aesthetic market and its commitment to the customer experience align perfectly with my track record of building innovative, high-performing consumer businesses." Tatjana Mitchell.
• "I look forward to partnering with the team to deliver on our strategic and financial objectives as Evolus strengthens its leadership in performance beauty." Tatjana Mitchell.

Industry Context

The appointment of a CFO with a strong background in high-growth consumer businesses, retail, and technology aligns with the broader trend in the performance beauty and aesthetic injectable market, which is increasingly driven by consumer engagement, digital platforms, and strategic scaling. Evolus aims to redefine this market with its customer-centric business model and innovative digital platform, making a CFO with experience in scaling brands and driving operational excellence particularly relevant for navigating competitive dynamics and expanding global footprint.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions "uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements" as a risk factor, indicating ongoing legal or regulatory compliance considerations related to past agreements.

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO could be viewed positively, potentially leading to improved financial management, strategic execution, and ultimately, enhanced shareholder value. The equity grants align the CFO's interests with shareholders.
• Employees: A strong finance leader can provide stability and clear financial direction, potentially benefiting overall company morale and strategic alignment.
• Customers: Improved financial health and strategic execution could support continued investment in product development and customer experience, benefiting customers of Jeuveau and Evolysse.
• Creditors: A seasoned CFO can enhance financial reporting and management, potentially improving the company's creditworthiness and relationships with creditors.

Next Steps

• Tatjana Mitchell will begin her employment as CFO on September 8, 2025.
• The company will grant Ms. Mitchell stock options and Restricted Stock Units (RSUs) on or promptly after the Start Date.
• The complete Employment Agreement will be filed with the SEC as an exhibit to the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
• The company plans to continue expanding its portfolio and global footprint.
• The company aims to deliver on strategic and financial objectives and strengthen its leadership in performance beauty.

Key Dates

Recommendation

The appointment of a highly qualified CFO is a positive development, signaling a focus on strengthening financial leadership and strategic execution. However, this filing primarily details an executive change and compensation, rather than providing new financial results or significant strategic shifts that would warrant a 'buy' or 'sell' recommendation. The company's forward-looking statements also reiterate existing risks. Investors should 'hold' and monitor future financial reports and strategic updates for more definitive performance indicators.

Keywords

Evolus, CFO Appointment, Tatjana Mitchell, Chief Financial Officer, EOLS, Executive Change, Financial Leadership, Aesthetic Injectables, Performance Beauty, Corporate Governance